At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CVRX CVRx, Inc.
Trading 10-12 09:54:21 EDT
1.60
+0.02
+1.27%
High1.67Low1.56Vol30.02K
Open1.58D1 Closing1.58Amplitude6.65%
Mkt Cap42.63MTradable Cap34.36MTotal Shares26.64M
T/O47.66KT/O Rate0.14%Tradable Shares21.47M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

CVRx to Present Late-Breaking Rebalance Registry Real-World Barostim Outcomes at HFSA 2026
Reuters  ·  09-30
CVRx to Present Late-Breaking Rebalance Registry Real-World Barostim Outcomes at HFSA 2026
Wall Street Analysts Are Neutral on Top Healthcare Picks
TIPRANKS  ·  09-23
Wall Street Analysts Are Neutral on Top Healthcare Picks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: CVRx (CVRX), Butterfly Network (BFLY) and Viridian Therapeutics (VRDN)
TIPRANKS  ·  09-22
Analysts’ Opinions Are Mixed on These Healthcare Stocks: CVRx (CVRX), Butterfly Network (BFLY) and Viridian Therapeutics (VRDN)
CVRx appoints veteran medtech executive as new CFO
TIPRANKS  ·  09-22
CVRx appoints veteran medtech executive as new CFO
Nyxoah Names Loic Moreau Interim CFO as John Landry Steps Down
MT Newswires Live  ·  09-22
Nyxoah Names Loic Moreau Interim CFO as John Landry Steps Down
CVRx Names New Chief Financial Officer
MT Newswires Live  ·  09-22
CVRx Names New Chief Financial Officer
CVRx appoints John Landry as CFO
TIPRANKS  ·  09-22
CVRx appoints John Landry as CFO
CVRx Names Nyxoah CFO John Landry as Finance Chief
Reuters  ·  09-22
CVRx Names Nyxoah CFO John Landry as Finance Chief
CVRx Appoints John Landry as Chief Financial Officer
THOMSON REUTERS  ·  09-22
CVRx Appoints John Landry as Chief Financial Officer
CVRx, - John Landry to Join CVRx on Oct 12, 2026 and Assume CFO Role After Q3 10-Q Filing
THOMSON REUTERS  ·  09-22
CVRx, - John Landry to Join CVRx on Oct 12, 2026 and Assume CFO Role After Q3 10-Q Filing
CVRx’s BAROSTIM Registry: Real‑World Hypertension Data That Could Move the Stock
TIPRANKS  ·  09-12
CVRx’s BAROSTIM Registry: Real‑World Hypertension Data That Could Move the Stock
BAROSTIM NEO Trial Update: Long-Term Hypertension Data in Focus for CVRX Investors
TIPRANKS  ·  09-12
BAROSTIM NEO Trial Update: Long-Term Hypertension Data in Focus for CVRX Investors
CVRx Says Board Reviews Options After Pointillist Letter, Sees Barostim Undervalued
Reuters  ·  08-25
CVRx Says Board Reviews Options After Pointillist Letter, Sees Barostim Undervalued
CVRx, Inc.: Board is Open to Constructive Engagement with All of Its Shareholders
THOMSON REUTERS  ·  08-25
CVRx, Inc.: Board is Open to Constructive Engagement with All of Its Shareholders
CVRx, - Board Regularly Evaluates Options to Maximize Shareholder Value
THOMSON REUTERS  ·  08-25
CVRx, - Board Regularly Evaluates Options to Maximize Shareholder Value
CVRx Responds to Letter from Pointillist Family Office
GlobeNewswire  ·  08-25
CVRx Responds to Letter from Pointillist Family Office
CVRx Shareholder Chernett Urges Board to Start Immediate Sale Process to Strategic Buyer
Reuters  ·  08-24
CVRx Shareholder Chernett Urges Board to Start Immediate Sale Process to Strategic Buyer
Jorey Chernett, Owner of More than 5.5% of Outstanding Shares of CVRx, Calls on Board to Begin Immediate Process to Pursue Sale of the Company to a Strategic Acquirer
THOMSON REUTERS  ·  08-24
Jorey Chernett, Owner of More than 5.5% of Outstanding Shares of CVRx, Calls on Board to Begin Immediate Process to Pursue Sale of the Company to a Strategic Acquirer
Jorey Chernett: Calls on CVRx Board Initiate a Comprehensive Review of Strategic Alternatives
THOMSON REUTERS  ·  08-24
Jorey Chernett: Calls on CVRx Board Initiate a Comprehensive Review of Strategic Alternatives
CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy
THOMSON REUTERS  ·  08-24
CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy

Introduction

Company Name.
CVRx, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Issue price:
--